Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
The New York Times
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Cassava Sciences, a small biotechnology company based in Austin, Texas, announced it would stop the advanced clinical trial for an experimental Alzheimer’s drug, ending a long-contested bid for regulatory approval.
The company announced on Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with mild to moderate Alzheimer’s disease in the trial, which enrolled more than 1,900 patients.
“The results are disappointing for patients and their families who are living with this disease and physicians who have been looking for novel treatment options,” the company’s chief executive, Richard J. Barry, said in a statement.
These results were unsurprising to many dementia researchers, who had questioned why the trial had been allowed to proceed in the first place, since much of the drug’s underlying science had been called into question.
Studies that once seemed to support the drug have been retracted from scientific journals. A consultant researcher who helped conduct some of the drug’s foundational studies was charged with fraud by a federal grand jury for allegedly falsifying data to obtain research grants.
In September, the company settled with the Securities and Exchange Commission over allegations that Cassava had made misleading statements about the results of earlier clinical trial data. However, the company neither admitted nor denied wrongdoing.
In a landmark antitrust case, the government asked a judge to force the company to sell its popular Chrome browser.
Eric Kim roasted dozens of birds and taste-tested eight different recipes before landing on this clever approach.
Republicans in Congress are eyeing cuts to Medicaid, which could threaten health coverage for tens of millions of poor Americans.
A second Trump administration could alter the lives of all sorts of animals, whether they live in laboratories, zoos, fields or forests.
An analysis of newly released 19th-century census records offers more insight into the conflict’s costs.
President-elect Donald J. Trump joined Elon Musk, as his company’s prototype moon and Mars rocket carried out a sixth test flight that showed a mix of progress and setbacks.
These abundant vegetarian dishes from Melissa Clark aren’t just gorgeous. They’re sure to make everyone at the table happy.
Some women are stocking up on the medications, saying they are concerned that the new administration could take steps to restrict access.
As the glaciers of South America retreat, the supply of freshwater is dwindling and its quality is getting worse.
It’s something turkey often isn’t — undeniably juicy and a guaranteed crowd-pleaser.
A rise in the disease in younger people was not followed by an increase in deaths, a study found, and might be a sign of overdiagnosis.